Our scientific understanding of the efficacy of
active cannabinoids from the cannabis plant, like THC, the primary psychoactive
component, and CBD, a non-psychoactive component, has been systematically
hampered by legislation for decades. As a growing body of medical and now even
clinical data on the pharmacology of cannabinoids and the human body’s
endocannabinoid system emerges however, in the U.S. alone, laws restricting
marijuana, especially medical marijuana (MMJ), have been falling left and
right. Minnesota and New York have recently both approved some form of MMJ
legislation and MMJ is now legal in 23 states, as well as D.C., opening up a
massive market opportunity, with companies like GW Pharmaceuticals (NASDAQ:
GWPH) already seeing considerable upside from their growing pipeline of
cannabinoid indications, like their Multiple Sclerosis spasticity and
neuropathic pain drug Sativex®.
One of the major areas of cannabinoid research
today is in treating neurological disorders and their effects, with a recent
high-water mark being seen in the FDA approval of a CBD study in childhood
epilepsy at the Comprehensive Epilepsy Center of New York University. This
clinical trial of CBD in epilepsy would put highly quantified data down to
extend the growing acceptance of MMJ, expanding data points like the successful
use of the CBD-rich and essentially non-psychoactive Charlotte’s Web strain of
cannabis to treat Dravet Syndrome (a form of severe and intractable epilepsy)
in the Charlotte Figi case. The dramatic reduction of crippling seizures seen
in the case of this one eight-year-old girl, whose story was made famous by
chief of neurosurgery at Atlanta’s Grady Memorial Hospital, Dr. Sanjay Gupta,
is one of the watershed moments in the MMJ industry and seemed to many in the
medical community to validate earlier studies done by Stanford University
showing an 84% seizure frequency reduction rate in children treated with a
variety of (artisanal) CBD.
The growing understanding of the endocannabinoid
system, as well as the crucial effects the CB1 and CB2 receptors play in
regulating multiple neurological and physiological processes within the body,
has led to growing acceptance in the medical community of MMJ and sparked a
firestorm of pharmacological development work in CBD by numerous companies. The
palliative care market in cancer alone for instance is huge, with tolerability
of even chronic MMJ usage a leading factor among pain relief vectors helping to
establish overall acceptance. Established opioid developers like (NASDAQ: CARA)
are even getting into the game, developing products like their CR701 compound
for neuropathic bodily pain as an alternative to comparably dangerous opioids,
which may not even work for some patients who have opioid resistant pain.
One of the smaller hot properties in the
burgeoning MMJ field today, and one which already has a functional
orally-administered cannabinoid product, Cannabics Pharmaceuticals (OTCQB:
CNBX), is a superb way for investors to get in on the action. CNBX’s flagship
indication, Cannabics SR, is ideally suited to states in the U.S. like
Minnesota, where only non-smokable MMJ preparations are currently permitted.
Cannabics SR is a proprietary preparation of pure cannabinoids in capsule form
designed for cancer patients as palliative care, yet its ingredients have
immediate and broader applications as well, applications that are becoming
increasingly apparent to healthcare professionals throughout the industry.
Cannabics SR has been shown in observational studies to provide a solid 10 to
12 hours of steady-state therapeutic effects, making it an ideal indication for
a safe and convenient once-daily dosing regimen.
Cannabics Pharmaceuticals has specifically
developed Cannabics SR to deliver an effective one-two punch, using a dual
delivery of oil-based compounds in order to provide both quick onset of
therapeutic effects within the first 20 to 60 minutes, as well as long-lasting
relief via a more concentrated cannabinoid portion within the capsule. This
proprietary, sustained release formulation is prepared in GMP (Good
Manufacturing Practices) certified facilities and the company has received
certification from the Israeli Ministry of Health for an advanced R&D
laboratory dedicated to cannabinoid science as well, a lab which they intend to
utilize in pursing the cannabinoid-based anti-cancer therapy end of the
spectrum further. The company has recently engaged with Mountain High Products
LLC, Owner of the “WANA edibles” brand, for the commercialization of its
products in the booming Colorado MMJ market. The company has also recently
secured an IP licensing and collaboration agreement for the production and
distribution of Cannabics SR in Spain with established regional entity Kalapa
Holding, which has made a name for itself advancing a tailored medical cannabis
therapy approach to the market, emphasizing direct connections between patients
and doctors. Cannabics Pharmaceuticals is at the forefront of commercializing
clinically tested cannabis-based products and is currently on-track to launch a
series of clinical studies in leading medical centers across Israel, where the
company’s R&D division is strategically located
With the domestic MMJ market estimated at around
$2B annually by IBISWorld, on a CAGR of around 16.2%, CNBX’s move to tackle not
just the U.S. market, but the EU and elsewhere, should make investor’s ears
perk up. GlobalData pegs the neuropathic pain market alone at around just under
$3B, with a projected CAGR of 3.19% through 2022, when they estimate the market
will have grown to approximately $3.5B. Needless to say, there is a massive,
target-rich environment for CNBX’s advanced cannabinoid medicines both at home
and abroad, and as their pipeline develops further amid prevailing legislative
acceptance of MMJ, shareholders stand poised to reap the rewards, while also
helping patients in dire need.
To learn more about Cannabics Pharmaceuticals,
visit: www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment